|
|
|
|
|
PEER-TO-PEER CLINICAL CONVERSATIONS |
|
|
|
|
|
|
Treatment Sequencing in Castrate-Resistant Metastatic Cancer
|
|
Mark Fleming, MD
|
| In this conversation with Charles Ryan, Mark Fleming speaks to the complex therapeutic landscape and offers guidance in managing treatment sequencing amongst the numerous treatment options in each disease state of advanced prostate cancer.
|
|
|
|
|
|
|
|
|
|
|
|
| Patient Preference Study Evaluating Darolutamide and Enzalutamide in Men with mCRPC |
| Karim Fizazi, MD, Ph,D. |
| In this conversation with Alicia Morgans, Karim Fizazi shares trial results from the phase II ODENZA trial presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting. Dr. Fizazi details the trial design, the primary endpoint: patient preference between the two treatments, as assessed by a questionnaire at week 24, and results of the study. |
|
|
|
|
|
|
|
|
|
|
|
| Beyond the Androgen Receptor: New Avengers in the Treatment of Castrate-Resistant Metastatic Cancer |
| Does the Treatment Sequence Matter? Resolving the Controversies
|
| Mark Fleming, MD
|
| At ASCO 2021, Mark Fleming discussed treatment sequencing in advanced prostate cancer within a session entitled “Beyond the Androgen Receptor: New Avengers in the Treatment of Castrate-Resistant Metastatic Cancer”. Dr. Fleming highlighted the importance of previous treatment administered, metastatic site, and symptoms in guiding treatment choice. However, there is no definitive sequence and treatment needs to be personalized to patient, disease, and treatment considerations. As we move forward, treatment will be increasingly guided by a biologic understanding of disease.
|
|
|
|
|
|
| The New Avengers in the Treatment of Prostate Cancer
|
| Johann de Bono, MB ChB FRCP MSc Ph.D. FMedSci
|
| At ASCO 2021, Johann de Bono discussed emerging treatment options in advanced prostate cancer within a session entitled “Beyond the Androgen Receptor: New Avengers in the Treatment of Castrate-Resistant Metastatic Cancer.” He emphasized that there are a rapidly increasing number of treatment options. As a result, men with advanced prostate cancer are living longer than before.
|
|
|
|
|
|
|
|
|
|
|
| Do Our Treatments Drive a New Resistant Mutational Phenotype?
|
| Ana Aparicio, MD
|
| At ASCO 2021, Ana Aparicio discusses the potential for currently utilized treatments in advanced prostate cancer to drive a new resistant mutational phenotype within a session entitled “Beyond the Androgen Receptor: New Avengers in the Treatment of Castrate-Resistant Metastatic Cancer.”
|
|
|
|
|
|
| Poster Discussion Session - Prostate |
| Immunogenic Priming with 177Lu-PSMA-617 Plus Pembrolizumab in Metastatic Castration-Resistant Prostate Cancer: A phase 1b study |
| Rahul Aggarwal, MD |
| Rahul Aggarwal presented data assessing whether a single dose of Lu can induce an immunogenic priming effect to improve outcomes of men with mCRPC subsequently treated with the immune checkpoint inhibitor pembrolizumab. A single priming dose 177Lu-PSMA-617 followed by pembrolizumab was well tolerated and leads to durable responses in a subset of mCRPC without high mutational burden or microsatellite instability. |
|
|
|
|
|
| First Results from a Randomized Phase II Study of Cabazitaxel vs an Androgen Receptor Targeted Agent in Patients with Poor-Prognosis Castration-Resistant Prostate Cancer |
| Kim van der Zande, Ph.D. |
| Kim van der Zande presented results of the OSTRICh trial which randomized patients with poor-prognosis mCRPC following progression on docetaxel to cabazitaxel or an androgen receptor-targeted agent. There was no significant difference between the clinical benefit of cabazitaxel and androgen receptor-targeted agents in this population of patients with poor-prognosis mCRPC though radiographic assessment favored patients treated with cabazitaxel and PSA-based metrics favored patients treated with androgen receptor-targeted agents. |
|
|
|
|
|
| ODENZA: A French Prospective, Randomized, Open-Label, Multicenter, Cross-over Phase II Trial of Preference Between Darolutamide and Enzalutamide in Men with Asymptomatic or Mildly Symptomatic Metastatic Castrate-Resistant Prostate Cancer |
| Emeline Colomba |
| Emeline Colomba presented results of the ODENZA trial to assess whether differences in toxicity affect patient preference among those with early mCRPC. A numerically greater number of patients with early mCRPC preferred darolutamide compared with enzalutamide, though this was not significantly different. Fatigue was a key factor influencing patient preference. |
|
|
|
|
|
| Evaluation of PSA Progression After Initiation of Enzalutamide or Abiraterone: Real-World Data on mCRPC |
| Fernando López-Campos, MD |
| Fernando López-Campos evaluated the significance of an early PSA increase in mCRPC patients treated with enzalutamide or abiraterone. PSA progression at 4 weeks after enzalutamide or abiraterone is significantly associated with shorter OS and may help identify patients not benefitting from enzalutamide or abiraterone before clinical or radiographic progression. PSA pattern progression and its association with OS might differ depending on the drug used (enzalutamide or abiraterone). |
|
|
|
|
|
| Talazoparib, an Oral PARP Inhibitor for Men With mCRPC and DNA Damage Response Alterations: Detailed Safety Analyses From TALAPRO-1 Trial |
| Niven Mehra, MD, Ph.D. |
| Niven Mehra presented results of the TALAPRO-1 safety profile of talazoparib in men with mCRPC with the aim of understanding how patients with adverse events were managed during the trial. TALAPRO-1 is a single-arm, open-label, phase 2 study of talazoparib in patients with progressive mCRPC, measurable soft tissue disease, and DNA damage response mutations likely to sensitize to PARP inhibitors, who received ≥1 taxane-based chemotherapy and progressed on ≥1 novel hormonal therapy. |
|
|
|
|
|
|
|
| To view our full coverage of the 2021 ASCO Annual Meeting, visit the Conference Coverage section on UroToday.com |
|
|
|
|
|
 |
|
|
|
|
